Roetzheim R G, Pal N, Gonzalez E C, Ferrante J M, Van Durme D J, Krischer J P
Department of Family Medicine, University of South Florida, Tampa 33612, USA.
Am J Public Health. 2000 Nov;90(11):1746-54. doi: 10.2105/ajph.90.11.1746.
We hypothesized that health insurance payer and race might influence the care and outcomes of patients with colorectal cancer.
We examined treatments received for all incident cases of colorectal cancer occurring in Florida in 1994 (n = 9551), using state tumor registry data. We also estimated the adjusted risk of death (through 1997), using proportional hazards regression analysis controlling for other predictors of mortality.
Treatments received by patients varied considerably according to their insurance payer. Among non-Medicare patients, those in the following groups had higher adjusted risks of death relative to commercial fee-for-service insurance: commercial HMO (risk ratio [RR] = 1.40; 95% confidence interval [CI] = 1.18, 1.67; P = .0001), Medicaid (RR = 1.44; 95% CI = 1.06, 1.97; P = .02), and uninsured (RR = 1.41; 95% CI = 1.12, 1.77; P = .003). Non-Hispanic African Americans had higher mortality rates (RR = 1.18; 95% CI = 1.01, 1.37; P = .04) than non-Hispanic Whites.
Patients with colorectal cancer who were uninsured or insured by Medicaid or commercial HMOs had higher mortality rates than patients with commercial fee-for-service insurance. Mortality was also higher among non-Hispanic African American patients.
我们假设医疗保险支付方和种族可能会影响结直肠癌患者的治疗及预后。
我们利用该州肿瘤登记数据,研究了1994年佛罗里达州所有新发病例的结直肠癌患者(n = 9551)所接受的治疗。我们还通过比例风险回归分析控制其他死亡率预测因素,估计了(截至1997年)调整后的死亡风险。
患者所接受的治疗因其保险支付方的不同而有很大差异。在非医疗保险患者中,相对于商业按服务收费保险,以下几组患者的调整后死亡风险更高:商业健康维护组织(风险比[RR]=1.40;95%置信区间[CI]=1.18,1.67;P = 0.0001)、医疗补助(RR = 1.44;95% CI = 1.06,1.97;P = 0.02)以及未参保者(RR = 1.41;95% CI = 1.12,1.77;P = 0.003)。非西班牙裔非洲裔美国人的死亡率(RR = 1.18;95% CI = 1.01,1.37;P = 0.04)高于非西班牙裔白人。
未参保或由医疗补助或商业健康维护组织承保的结直肠癌患者的死亡率高于商业按服务收费保险的患者。非西班牙裔非洲裔美国患者的死亡率也更高。